On January 17, 2025, Biodexa Pharmaceuticals Plc entered into a securities purchase agreement with C/M Capital Master Fund for up to $35 million of newly issued shares, with a commitment fee of $875,000. This event is significant as the proceeds will be used to fund development projects and working capital.